NCT06952803
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06952803
Title A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation (EvoPAR-PR02)
Acronym EvoPAR-PR02
Recruitment Not yet recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | TUR | SWE | POL | ITA | HUN | FRA | FIN | ESP | DEU | CAN | BRA | BEL | AUT | AUS


No variant requirements are available.